Perimenopause Depression: HRT, CBT, Antidepressants & Evidence

Table of contents

• Evidence summary
• What perimenopausal depression is
• Symptoms and diagnosis
• Causes and risk factors
• Treatments that work
• Medicines: HRT, antidepressants and the new non-hormonal drugs
• Supplements and lifestyle claims
• Risks of common treatments
• Who to see
• Follow the money
• Related research
• Frequently asked questions
• Sources and funding notes

Evidence summary

Independent evidence and credibility scorecard

Independence tiers: 1 = regulator or government body; 2 = academic or Cochrane team with no declared commercial funding for the work; 3 = independent authors analysing mostly manufacturer-run trials, or minor declared industry ties; 4 = manufacturer-funded or manufacturer-authored. Credibility runs from A (highest) to D.

Most sources cluster in the US and UK, so this picture reflects two health systems with very different ways of paying for menopause care. Where publicly funded UK and US researchers agree with each other, and with what the industry-funded trials show for hot flushes, confidence rises.

What perimenopausal depression is

Perimenopause is the run-up to the last period. Cycles become irregular and hormone levels swing. Menopause is confirmed once there has been no period for 12 months (NICE NG23). It is not a formal diagnosis in its own right. "Perimenopausal depression" simply means depression, or depressive symptoms, that happen during this window.

NICE draws a line that matters for treatment. It separates depressive symptoms (some features of depression, but not enough for a diagnosis) from depression as defined by ICD-11 or DSM-5. Its HRT and CBT advice is aimed at the first group. For the second, it says to use the menopause guideline alongside NICE's depression guideline (NICE NG23, recs 1.5.21 to 1.5.23).

How common is it? A 2026 meta-analysis of 102 studies (over 1.1 million women) estimated that about 32% of perimenopausal women had depressive symptoms at any one time, and about 30% of postmenopausal women (Balasubramanian 2026). Anxiety symptoms were also common. These figures come mostly from screening questionnaires, which count more people than a clinical interview does, so they describe symptoms, not diagnosed illness.

The better test is whether risk actually changes as women move through the transition. Prospective studies, which follow the same women over time, say it does. Perimenopausal women had about 40% higher odds of depression than premenopausal women, while postmenopausal women showed no clear increase (Badawy 2024). In SWAN, women were two to four times more likely to have a major depressive episode during perimenopause or early postmenopause than before it, even after allowing for past depression, life stress, hot flushes and hormone levels (Bromberger 2011).

Symptoms and diagnosis

The NHS lists mood swings, low mood, anxiety, irritability, poor memory and "brain fog" among common menopause symptoms, often made worse by poor sleep and night sweats (NHS). Depression itself shows the usual signs: persistent low mood, loss of interest or pleasure, changes in sleep and appetite, tiredness, guilt, poor concentration, and thoughts of death.

The overlap is the problem. Poor sleep, fatigue and poor concentration can come from night sweats alone. The 2018 expert guideline on perimenopausal depression says menopause symptoms "complicate, co-occur, and overlap" with depression, and recommends assessing menopausal stage, menopause symptoms, psychosocial stresses and other causes, using a validated screening tool (Maki 2018).

Blood tests usually do not help. NICE says perimenopause should be identified from symptoms and cycle changes, without laboratory tests, in otherwise healthy women aged 45 or over. It advises against using oestradiol, anti-Müllerian hormone or inhibin tests for this purpose, and limits FSH testing to particular groups, such as women aged 40 to 45 (NICE NG23, 1.3). Hormone levels swing day to day in perimenopause, so a single result says little. A clinician may still check thyroid function or blood count, because these can cause low mood and tiredness.

Causes and risk factors

The exact cause is not known. The leading idea is that some women's brains are sensitive to changing oestrogen levels, rather than to low levels as such. Two findings support this. Risk is highest in the transition, when levels fluctuate, and not in later postmenopause, when they are steadily low (Badawy 2024). And in SWAN, the higher risk in perimenopause held even after allowing for measured hormone levels (Bromberger 2011). So a single blood level does not predict who becomes depressed. The mechanism has not been proven in humans.

Risk factors with reasonable support:

• Past depression. The strongest predictor in SWAN (Bromberger 2011). Most women with major depression in perimenopause have had an earlier episode (Maki 2018).
• Family history of depression. In a later SWAN analysis of 303 women, a family history roughly doubled the odds of midlife major depression (OR 2.24, 95% CI 1.17 to 4.29), independent of personal history and menopausal stage (Colvin 2017).
• Stressful life events. In the Gordon trial, recent stressful events made the mood benefit of oestradiol larger, which suggests stress and hormone change interact (Gordon 2018).
• Hot flushes and poor sleep. These often travel with low mood. NHS and NICE both note that sleep loss worsens mood and concentration (NHS). In SWAN, however, the stage effect on depression was not explained by hot flushes alone.
• Early or sudden menopause. NICE says distress from earlier-than-expected menopause may need referral to psychology services (NICE rationale).

A history of premenstrual dysphoric disorder or postnatal depression is often cited as a sign of hormone sensitivity. We did not find a source we could open that measured this link with clear numbers, so we treat it as plausible rather than established.

Treatments that work

The NICE approach for England and Wales, updated in 2024, is:

• Depressive symptoms (not full depression) starting with other menopause symptoms: consider HRT (rec 1.5.21).
• Depressive symptoms with hot flushes: consider CBT, on its own or added to other options (rec 1.5.22).
• Suspected or diagnosed depression: follow both the menopause guideline and the NICE depression guideline (rec 1.5.23). In practice that means talking therapies and antidepressants are on the table as for anyone else.

The 2018 North American guideline, from The Menopause Society and the National Network of Depression Centers, reached a similar view: proven depression treatments (antidepressants and psychotherapy) are first line for perimenopausal major depression, and oestrogen has some antidepressant evidence, mainly for women in perimenopause with hot flushes. It found no evidence to recommend botanical or alternative remedies (Maki 2018; MDedge summary).

The two guidelines differ slightly in emphasis. NICE puts HRT first for menopause-linked low mood that falls short of depression, while the North American panel puts depression treatments first once depression is diagnosed. They do not contradict each other.

CBT: what the trials show

Menopause-specific CBT teaches ways to handle hot flushes, sleep problems and the thoughts that make them worse, as well as standard CBT for mood. In the UK MENOS 2 trial (n=140), group and self-help CBT both cut how problematic hot flushes felt by about two points on a ten-point scale at six weeks, with improved mood at six weeks (Ayers 2012). It was funded by the NIHR Biomedical Research Centre at the South London and Maudsley NHS Trust and King's College London (protocol). In a Canadian trial of 71 women, a broader programme called CBT-Meno improved depressive symptoms, sleep and hot-flush interference compared with a waiting list, and the gains lasted three months (Green 2019). Pooled across 30 trials, CBT reduced depression scores by a small-to-moderate amount (d −0.33) (Spector 2024).

NICE was candid that its own review of CBT for menopausal mood was mixed. Most of the evidence showed no difference from usual care on depressive symptoms, some showed benefit, and none showed harm. NICE recommended it anyway because CBT is an established treatment for depression in general (NICE rationale). In the fezolinetant appraisal, consultation responses and patient and clinical experts told NICE that CBT does not reduce physical symptoms for many people and has long waiting lists (NICE TA1143).

Medicines: HRT, antidepressants and the new non-hormonal drugs

HRT (menopausal hormone therapy)

The strongest mood evidence is for oestradiol given through the skin to women still in perimenopause. In a Harvard trial of 50 perimenopausal women with major, minor or chronic depression, a 100 µg oestradiol patch for 12 weeks led to remission in 68% compared with 20% on placebo (Soares 2001). In an NIMH trial of 34 women, 80% responded to oestradiol compared with 22% on placebo, whether or not they had hot flushes (Schmidt 2000). Both trials were small and short.

Prevention has one good trial. Among 172 women aged 45 to 60 who were not depressed at the start, a year of oestradiol patches plus periodic progesterone halved the rate of clinically significant depressive symptoms (17.3% vs 32.3%). The benefit was seen in the early transition, not in late perimenopause or after menopause (Gordon 2018).

After menopause, the picture is weaker. In KEEPS, recently postmenopausal women who were mostly not depressed showed a small improvement in mood scores on oral conjugated oestrogens, but not on oestradiol patches, and no change in depression scores (Gleason 2015). A 2026 meta-analysis of 12 randomised trials in perimenopausal women found a small average benefit over placebo (SMD −0.23, 95% CI −0.43 to −0.03). In plain terms, the average woman on HRT scored a little better than the average woman on placebo, and the authors rated certainty as limited (Li 2026).

HRT is not licensed to treat depression. The NHS says it can relieve "anxiety and low mood caused by menopause" (NHS). Data on oestrogen combined with a progestogen, which women with a womb need, are sparse and inconclusive for mood (Maki 2018).

Antidepressants (SSRIs and SNRIs)

For diagnosed depression in midlife, antidepressants are used as for anyone else. The 2018 guideline found data suggesting some SSRIs and SNRIs work at usual doses in perimenopausal women (MDedge). See our guides to escitalopram, venlafaxine and paroxetine.

These drugs also reduce hot flushes, at lower doses and by a modest amount. In the NIH-funded MsFLASH trial (n=205), escitalopram 10 to 20 mg a day led to 1.41 fewer hot flushes a day than placebo after 8 weeks, and 55% vs 36% of women halved their flushes (Freeman 2011). Flushes returned within three weeks of stopping. Paroxetine 7.5 mg (Brisdelle) was approved by the FDA in 2013 for hot flushes after two trials in 1,184 women (Simon 2013; HealthDay).

NICE says not to routinely offer SSRIs, SNRIs or clonidine as first-line treatment for hot flushes alone (rec 1.5.4). The North American Menopause Society's 2023 position statement recommends them as a non-hormonal option (NAMS 2023). For a woman with both depression and hot flushes, an antidepressant may help both, but that has not been tested well in its own trials.

Fezolinetant and elinzanetant

These are a new class of non-hormonal pills that block neurokinin receptors in the brain's temperature-control centre. Fezolinetant (Veozah in the US, Veoza elsewhere; Astellas) was approved by the FDA in May 2023 (FDA). In SKYLIGHT 1, the 45 mg dose cut moderate-to-severe hot flushes by about 2.5 a day more than placebo at 12 weeks (Lederman 2023). The trial authors themselves wrote that the drug's effect on quality of life, including mood symptoms, "merits investigation". NICE recommended fezolinetant in March 2026 for moderate to severe hot flushes when HRT is unsuitable. It noted that indirect comparisons suggest it may work about as well as other non-hormonal treatments, but this is uncertain (NICE TA1143).

Elinzanetant (Lynkuet; Bayer) blocks two neurokinin receptors. It was approved by the FDA in October 2025 (Contemporary OB/GYN). In the OASIS 1 and 2 trials it reduced hot flushes by about 3 a day more than placebo at 12 weeks, and it improved sleep and menopause quality-of-life scores (Pinkerton 2024). Neither drug has been shown to treat depression.

Testosterone

Testosterone is widely promoted online for energy, mood and "brain fog". The 2019 Global Consensus Position Statement, signed by several international menopause and endocrine societies, found no effect on general wellbeing and no effect on depressed mood. The only evidence-based use is for low sexual desire causing distress in postmenopausal women (Davis 2019). A meta-analysis of 36 trials (8,480 women), funded by Australia's NHMRC, confirmed the benefit for sexual function, with more acne and hair growth (Islam 2019). NICE says to consider testosterone only for low sexual desire when HRT alone has not helped (rec 1.5.25).

Supplements and lifestyle claims

NICE tells clinicians to explain that the safety, quality and purity of unregulated preparations may be unknown, and that the efficacy and safety of unregulated hormone preparations (often sold as "bioidentical") are unknown (NICE NG23, 1.4.5 and 1.4.6).

• Black cohosh Insufficient: a Cochrane review of 16 trials (2,027 women) found no difference from placebo in hot flushes (0.07 flushes a day) or menopause symptom scores, and HRT worked better (Leach 2012). NICE says there is "some evidence" for it but notes variable products and interactions (NICE 1.4.7). See our guide to supplement-related liver injury.
• Soy isoflavones and red clover Insufficient: a Cochrane review of 43 trials found no conclusive evidence. Pooled red clover data showed no significant effect; some high-genistein extracts may reduce flushes; placebo effects were large (Lethaby 2013). Neither review assessed depression as a main outcome.
• St John's wort Weak for menopause: NICE advises people with, or at high risk of, breast cancer that there is some evidence it may ease hot flushes, but uncertainty about dose, product strength and potential serious interactions, including with tamoxifen, anticoagulants and anticonvulsants (NICE 1.4.8). See our St John's wort review.
• Combination "menopause relief" supplements: the US Federal Trade Commission alleged in 2015 that the makers of Amberen made unsubstantiated claims that it relieved nearly every menopause symptom, including irritability, and false claims that it was clinically proven. The company and its principals settled in 2016 (FTC).
• Exercise Moderate as an add-on: the 2018 guideline recommends it as a complement to therapy and medicines for perimenopausal depression (MDedge). The Menopause Society did not recommend exercise or yoga specifically for hot flushes (NAMS 2023).
• Mindfulness Moderate for anxiety: pooled anxiety effect d −0.56, depression d −0.27 (Spector 2024).
• Sleep: NICE says to consider menopause-specific CBT for sleep problems linked to night sweats (rec 1.5.24). See our CBT-I guide.

Risks of common treatments

HRT. The NHS says combined HRT taken for 5 years leads to around 5 extra breast cancers per 1,000 women. Oestrogen-only HRT carries little or no increase. Tablets slightly raise the risk of blood clots and stroke, while patches, gels and sprays do not raise clot risk (NHS). The MHRA, drawing on a pooled analysis of 108,647 breast cancer cases, says some excess risk persists for more than 10 years after stopping, and that use under a year adds little or no risk (MHRA). Progestogens can cause mood side effects in some women, a common reason to switch type or route; we did not find a trial measuring this that we could open.

SSRIs and SNRIs. Common effects include nausea, headache, sleep changes and sexual side effects. Antidepressant labels carry a boxed warning on suicidal thoughts in young people. Paroxetine can reduce the effect of tamoxifen, which matters for breast cancer survivors seeking non-hormonal options (HealthDay, citing FDA). Stopping can cause withdrawal symptoms; see our guide to antidepressant withdrawal.

Testosterone. Acne and unwanted hair growth are more common; oral forms worsen cholesterol (Islam 2019). The consensus statement advises against pellets, injections and doses giving male-range levels (Davis 2019).

Supplements. Unknown purity and variable dose. St John's wort interacts with many medicines, including tamoxifen (NICE).

Who to see

• GP or primary care clinician first. NICE expects menopause to be identified from symptoms in most women over 45, without blood tests, and HRT and CBT can be started in primary care (NICE NG23).
• Talking therapies (NHS Talking Therapies in England) for CBT, including menopause-focused CBT where available.
• A healthcare professional with expertise in menopause if treatment is not working, side effects are a problem, or there is a history such as breast cancer, clots or stroke (NICE recs 1.5.26 onwards).
• Mental health services for severe or recurrent depression, bipolar disorder, psychosis or suicide risk.

Bring a short symptom diary: periods, hot flushes, sleep and mood day by day. It helps separate cyclical, menopause-linked symptoms from persistent depression. Related conditions are covered in our guides to PMDD and perinatal depression.

Follow the money: who makes it and who funded the evidence

Who funds the mood research

The core evidence on menopause and depression is publicly funded. SWAN is co-sponsored by the NIH's National Institute on Aging, National Institute of Nursing Research, Office of Research on Women's Health and the complementary health centre (SWAN). The prevention trial was paid for by NIMH and NCATS (Gordon 2018). The UK CBT trials came from NHS-linked NIHR research funding (MENOS 2 protocol). MsFLASH was an NIH cooperative agreement, but Forest supplied the escitalopram and several lead authors reported industry fees and grants (Freeman 2011). KEEPS was funded by the NIH and by the Aurora Foundation through the Kronos Longevity Research Institute, with drugs supplied by Bayer and Abbott (Gleason 2015).

Who makes the treatments

• Fezolinetant: Astellas Pharma, headquartered in Tokyo, Japan. When it was approved in 2023, Astellas projected yearly sales of ¥300 billion (about $2.2 billion) by fiscal 2025 (Bloomberg via Daily Maverick). Actual sales in the year to March 2026 were ¥46.6 billion, and the company now gives a peak-sales range of ¥150 to 250 billion (Astellas results).
• Elinzanetant: Bayer (Germany). Bayer sponsored the OASIS trials and had a role in design, analysis, write-up and the decision to publish (OASIS 1 and 2).
• Low-dose paroxetine (Brisdelle): marketed by Noven Therapeutics, Miami (HealthDay).
• HRT and antidepressants are mostly off-patent and made by many generic manufacturers.

Professional societies and guideline panels

The Menopause Society (formerly the North American Menopause Society) runs a Corporate Liaison Council for companies with a business interest in menopause, which they join by paying annual dues of $10,000. Its 2026 members are Amgen, Astellas, Bayer, Bonafide Health, i-Health, LifeMD and Progyny (Menopause Society). The Society co-led the 2018 depression guideline and the 2023 non-hormone position statement, which recommends fezolinetant (NAMS 2023). Several SKYLIGHT 1 authors declared roles with Astellas, and one sat on the Society's board (SKYLIGHT 1 declarations). This does not make the recommendations wrong. It is a reason to weigh them alongside NICE, which reached its fezolinetant decision through a separate cost-effectiveness process.

Documented controversies

• Ghostwriting in the 1990s and 2000s. Documents from litigation over Wyeth's Prempro showed Wyeth worked with medical communication firms, mainly DesignWrite, to produce journal articles promoting its hormone products. The author of the analysis disclosed she was a paid expert witness for plaintiffs (Fugh-Berman 2010).
• Online HRT claims. A study of the 180 most visible HRT claims on UK social media and search found that 67.2% went beyond BNF and NICE indications and 77.2% were linked to a conflict of interest, often private clinics, drug-industry funding or menopause products (McCartney 2025).
• US boxed warning removal (2025). In November 2025 the FDA announced it would remove boxed warnings about heart disease, breast cancer and probable dementia from HRT labels, keeping the endometrial cancer warning for oestrogen-only products, after an informal expert panel in July (RAPS). Critics, including the National Center for Health Research, said such panels do not require conflict-of-interest disclosures and that most members stood to gain from the change (Inside Health Policy, reposted by NCHR). UK labelling and NICE advice were not changed by this.
• Supplement marketing. The FTC case against Amberen's makers ended in a $40 million judgment, all but $250,000 suspended because of inability to pay (FTC).

What this means: The finding that depression risk rises in perimenopause, and that oestradiol and CBT can help, rests mainly on publicly funded US and UK research. The evidence for the newest hot-flush drugs comes from their makers, and those makers also fund the main professional society in North America. On mood specifically, no maker has shown its non-hormonal drug treats depression, so claims that these drugs fix menopausal low mood go beyond the data.

Related research

For wider, evidence-graded context, see these Pure City Research guides:

• Major depressive disorder
• Perinatal depression
• Premenstrual dysphoric disorder
• Cognitive behavioural therapy
• CBT for insomnia
• Generalised anxiety disorder
• Escitalopram
• Venlafaxine
• Paroxetine
• St John's wort
• Women and cardiovascular disease
• Supplements for stress, anxiety and depression

Frequently asked questions

Sources and funding notes

What we could not verify: the funding statements for the Soares 2001 and Simon 2013 (low-dose paroxetine) trials, which were not in the PubMed records we could open; the full funding statements of the Green 2019 and Ayers 2012 CBT trials beyond the MENOS 2 protocol; the full Cochrane funding notes; the Maki 2018 guideline's own funding section (we relied on a news summary for author conflicts); the declarations of interest of NICE's NG23 committee members; and the content of a 2025 BMJ investigation on menopause advocacy and US policy, which was blocked to us. We did not find an openable source quantifying risk from past PMDD or postnatal depression, or a trial of progestogen-related mood effects. The Veozah sales figure is from a company slide; the 2023 forecast is from a news report of a company statement. Global market-size estimates were from market-research firms and are not used.

1. NICE NG23: Menopause: identification and management (2015, updated 2024, last revised April 2026) — UK guideline; NICE is funded by the Department of Health and Social Care.
2. NICE NG23 rationale and impact — evidence summary for CBT and mood; NICE.
3. NICE TA1143: Fezolinetant (March 2026), recommendation and committee discussion — UK appraisal; company evidence from Astellas.
4. NICE NG222: Depression in adults — UK guideline; NICE.
5. FDA Drug Safety Communication: Veozah and liver injury (September 2024, boxed warning December 2024) — US regulator.
6. MHRA Drug Safety Update: HRT and breast cancer risk (2019) — UK regulator.
7. NHS: Menopause symptoms; NHS: Benefits and risks of HRT; NHS: Urgent mental health help — UK public health service.
8. Bromberger JT et al. Major depression during and after the menopausal transition: SWAN. Psychol Med 2011 — cohort; NIH (NIA, NINR, NIMH, NICHD, NHLBI); no conflicts. SWAN study site.
9. Colvin A et al. Family history of depression and the menopausal transition: SWAN. Depress Anxiety 2017 — cohort; NIA, NIMH and NINR; no conflicts declared.
10. Badawy Y et al. The risk of depression in the menopausal stages. J Affect Disord 2024 — meta-analysis; UCL; no funding listed, nothing to declare.
11. Balasubramanian I et al. Prevalence and incidence of depressive, anxiety and insomnia symptoms in peri- and postmenopausal women. Gen Hosp Psychiatry 2026 — meta-analysis; JIPMER, India; no competing interests.
12. Maki PM et al. Guidelines for the evaluation and treatment of perimenopausal depression. Menopause 2018 — expert guideline; The Menopause Society and National Network of Depression Centers; several authors with industry ties (MDedge summary).
13. Soares CN et al. Efficacy of estradiol for depressive disorders in perimenopausal women. Arch Gen Psychiatry 2001 — RCT; Massachusetts General Hospital; funding not in PubMed record.
14. Schmidt PJ et al. Estrogen replacement in perimenopause-related depression. Am J Obstet Gynecol 2000 — RCT; NIMH intramural programme.
15. Gordon JL et al. Transdermal estradiol and micronized progesterone in the prevention of depressive symptoms. JAMA Psychiatry 2018 — RCT; NIMH and NCATS; no conflicts reported.
16. Li Y et al. Menopausal hormone therapy for depressive symptoms in perimenopausal women. J Affect Disord 2026 — meta-analysis; Hangzhou, China; no competing interests.
17. Gleason CE et al. KEEPS-Cognitive and Affective Study. PLoS Med 2015 (full text) — RCT; NIH and Aurora Foundation via Kronos Longevity Research Institute; drugs from Bayer and Abbott.
18. Spector A et al. Psychosocial interventions for non-physiological symptoms of menopause. J Affect Disord 2024 — meta-analysis; UCL; no competing interests.
19. Ayers B et al. MENOS 2. Menopause 2012 — RCT; funded by NIHR Biomedical Research Centre, South London and Maudsley/King's College London (protocol).
20. Green SM et al. CBT-Meno randomised trial. Menopause 2019 — RCT; McMaster University, Canada; funding not verified.
21. Freeman EW et al. Escitalopram for hot flashes (MsFLASH). JAMA 2011 (full text) — RCT; NIH; drug from Forest; authors with industry ties.
22. Simon JA et al. Low-dose paroxetine 7.5 mg for vasomotor symptoms. Menopause 2013 — two phase 3 RCTs; funding statement not in PubMed record, but one author is listed at Noven Pharmaceuticals, the maker. HealthDay on FDA approval.
23. Lederman S et al. SKYLIGHT 1. Lancet 2023 — RCT; funded by Astellas; authors with Astellas ties.
24. Pinkerton JV et al. OASIS 1 and 2. JAMA 2024 (full text) — RCTs; sponsored by Bayer. FDA approval report.
25. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause 2023 — society statement; corporate council includes drug makers.
26. Davis SR et al. Global Consensus Position Statement on testosterone therapy for women. J Clin Endocrinol Metab 2019 — multi-society consensus.
27. Islam RM et al. Safety and efficacy of testosterone for women. Lancet Diabetes Endocrinol 2019 — meta-analysis; Australian NHMRC.
28. Leach MJ, Moore V. Black cohosh for menopausal symptoms. Cochrane 2012 — systematic review; no competing interests.
29. Lethaby A et al. Phytoestrogens for menopausal vasomotor symptoms. Cochrane 2013 — systematic review; one author wrote two included trials.
30. McCartney M et al. Online information about HRT vs BNF and NICE. BMJ Open 2025 — cross-sectional; St Andrews student scholarship.
31. Fugh-Berman AJ. The haunting of medical journals: how ghostwriting sold "HRT". PLoS Med 2010 — policy analysis; author was a paid plaintiffs' expert witness.
32. The Menopause Society: Corporate Liaison Council (2026) — society's own page.
33. FTC: Marketers of Amberen settle charges (May 2016) — US regulator.
34. RAPS: FDA to remove boxed warnings from hormone therapies (November 2025) — regulatory trade news; Inside Health Policy via National Center for Health Research — news and advocacy nonprofit.
35. Astellas FY2025 financial results presentation — company; Bloomberg report of 2023 forecast.

Educational research reviewed 6 October 2026. This article is not medical advice; talk to a qualified clinician or pharmacist before starting, stopping or combining treatments.